MiMedx Group (MDXG) 2025 Conference May 13, 2025 08:15 PM ET Speaker0 On the wound care front, our products are found in virtually every care setting where a patient presents with a chronic or hard to heal wound, and there are lots of them as you can see from this slide. Our portfolio is comprised of a number of products, but I'd like to focus on a few highlights from our portfolio for a moment. First up, EpiFix is our flagship product for the wound market, and as I mentioned, most widely recognized efficac ...

Core Insights - MiMedx Group, Inc. announced the publication of health economics data for the use of EPIFIX® in reconstructing cutaneous wounds after Mohs surgery, highlighting its cost-effectiveness and clinical success [1][2] Group 1: Study Findings - The study published in the Journal of Drugs in Dermatology analyzed 429 Mohs patients and demonstrated that DHACM significantly reduced adverse post-repair complications, with 97.2% of patients experiencing no complications compared to 78.7% with traditional methods [2] - Patients treated with placental allografts reached closure faster, with an average length of care of 33.3 days versus 48.3 days for those with autologous tissue repairs [2] Group 2: Industry Context - Mohs surgery is recognized as the gold standard for treating skin cancers, performed over 850,000 times annually in the U.S., primarily by dermatologists in outpatient settings [1] - The increasing evaluation of placental allografts like EPIFIX reflects a shift towards innovative approaches in high-risk surgeries, particularly as healthcare systems emphasize health economics in decision-making [2] Group 3: Company Overview - MiMedx is a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions through innovation [3]

MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Matt Notarianni - Head of Investor RelationsJoseph Capper - CEODoug Rice - Chief Financial OfficerCarl Byrnes - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRoss Osborn - Analyst Operator Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and ...

Financial Data and Key Metrics Changes - The company reported Q1 2025 net sales of $88 million, representing a 4% year-over-year growth despite a tough comparison from Q1 2024, which had an 18% growth [8][19] - Adjusted gross profit margin was 84% for the quarter, while GAAP gross margin was 81%, down from 85% in the prior year [21][25] - Adjusted EBITDA was $17 million, or 20% of net sales, compared to $19 million, or 22% of net sales in the prior year [25][27] - The company ended the quarter with $106 million in cash, an increase of $2 million during the quarter [8][26] Business Line Data and Key Metrics Changes - Surgical sales grew by 16% to $32 million, driven by strong performance from AmnioFect and HelioGen [20] - Wound sales declined by 2% to $56 million, facing challenges due to Medicare reimbursement disruptions [20][12] - The Amneal branded products, particularly Amnealophenic, grew by 22% in Q1 [11] Market Data and Key Metrics Changes - The company faced ongoing disruptions in the private office and associated care settings due to the current Medicare reimbursement system [6][12] - Approximately 25% of the company's overall business has ASP exposure, making it manageable despite the challenges [46] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio, focusing on developing unique product configurations to meet customer needs [10] - Strategic priorities include expanding the surgical market footprint, enhancing customer intimacy, and developing clinical evidence to support product use [15][18] - The company is actively pursuing opportunities for organic and inorganic growth to support business diversification [26] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the delay in Medicare reimbursement reforms but remains committed to advocating for necessary changes [29][32] - The company reiterated its full-year revenue growth outlook to be at least in the high single digits, with expectations for higher growth rates in the latter half of the year [31] - Long-term prospects remain positive, with expectations to reset top-line growth to low double digits post-reform [31][32] Other Important Information - The company has contingency plans in place to adapt to the current environment and maintain competitiveness [7][14] - Management emphasized the importance of generating cash flow, even during high cash burn periods [27] Q&A Session Summary Question: Adjusted gross profit margin expectations - Management acknowledged that the adjusted gross profit margin was 84.1% in Q1 and attributed future changes to product mix [35] Question: Progress on Equifax in Japan - Management indicated that growth in Japan is on track but remains relatively small in overall contribution [36] Question: Overall reimbursement landscape and confidence in future changes - Management expressed frustration over the lack of changes in the reimbursement landscape but remains hopeful for future reforms [40][46] Question: Shifting private office volumes to new products - Management stated that shifting volumes to higher-priced products is a necessary step to protect business but cautioned against expecting significant windfalls [48][52] Question: Surgical growth driven by HelioGen - Management noted that surgical growth was driven by better execution across the portfolio, with no specific new data driving volumes [53][55] Question: Preparing for a better market environment - Management highlighted ongoing efforts to expand product offerings and invest in commercial strength to prepare for future growth [58][61]